Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study (2021)
- Authors:
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; ZUARDI, ANTONIO WALDO - FMRP
- Unidade: FMRP
- DOI: 10.1590/1516-4446-2020-1416
- Subjects: COCAÍNA; CANABINOIDES; TRANSTORNOS RELACIONADOS AO USO DE SUBSTÂNCIAS; DEPENDENTES QUÍMICOS; MÉTODO DUPLO-CEGO
- Keywords: Crack-cocaine; Craving; Cannabidiol; Dependence
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Brazilian Journal of Psychiatry
- ISSN: 1809-452X
- Volume/Número/Paginação/Ano: v. 43, n. 5 , p.467-476, 2021
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
GAYA, Carolina de Meneses et al. Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Brazilian Journal of Psychiatry, v. 43, n. 5 , p. 467-476, 2021Tradução . . Disponível em: https://doi.org/10.1590/1516-4446-2020-1416. Acesso em: 19 abr. 2024. -
APA
Gaya, C. de M., Crippa, J. A. de S., Hallak, J. E. C., Miguel, A. Q., Laranjeira, R., Bressan, R. A., et al. (2021). Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Brazilian Journal of Psychiatry, 43( 5 ), 467-476. doi:10.1590/1516-4446-2020-1416 -
NLM
Gaya C de M, Crippa JA de S, Hallak JEC, Miguel AQ, Laranjeira R, Bressan RA, Zuardi AW, Lacerda ALT. Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study [Internet]. Brazilian Journal of Psychiatry. 2021 ; 43( 5 ): 467-476.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1590/1516-4446-2020-1416 -
Vancouver
Gaya C de M, Crippa JA de S, Hallak JEC, Miguel AQ, Laranjeira R, Bressan RA, Zuardi AW, Lacerda ALT. Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study [Internet]. Brazilian Journal of Psychiatry. 2021 ; 43( 5 ): 467-476.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1590/1516-4446-2020-1416 - Cannabidiol: an anxiolytic or an antipsychotic new drug?
- Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizopherenia: an update
- Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implication for neuroprotection
- Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Cannabidiol and neuroprotection: evidence from preclinical studies
- Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol
Informações sobre o DOI: 10.1590/1516-4446-2020-1416 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 003113788.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
